Tonix Pharmaceuticals (TNXP) announced the publication of a paper entitled, “Recombinant Chimeric Horsepox Virus, TNX-801, is Attenuated Relative to Vaccinia Virus Strains in Both In Vitro and In Vivo ...
How it works: experts take the patient's T-cells and reprogram them in the lab so that they can recognize structures on cancer cells with the help of a receptor called chimeric antigen receptor (CAR).